1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Pfizer/Celltrion Prep For October Inflectra Launch

 
• By Donna Young

With Celltrion shipping the first batch of its biosimilar Inflectra (infliximab-dyyb) and a stipulation agreement with Johnson & Johnson, Pfizer is set to launch the product on Oct. 3 – six months after it was approved in the US.

It looks like an Oct. 3 go for Pfizer Inc. and its partner Celltrion Inc. to launch their biosimilar Inflectra (infliximab-dyyb) after reports surfaced the first batch of the drug had been shipped and new court documents revealed the companies had entered into a new agreement with Johnson & Johnson unit Janssen Biotech Inc. to clear the way for US marketing.

Inflectra is a biosimilar version of J&J's blockbuster tumor necrosis factor Remicade.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.